U.S. License Holder:
New York Blood Center, Inc.
Date of License:
November-10-2011
Last Update:
Dec-15-2024
FDA-Approved Indications
HEMACORD (HPC, Cord Blood) is an allogeneic cord blood hematopoietic progenitor cell therapy indicated for use in unrelated donor hematopoietic progenitor cell transplantation procedures in conjunction with an appropriate preparative regimen for hematopoietic and immunologic reconstitution in patients with disorders affecting the hematopoietic system that are inherited, acquired, or result from myeloablative treatment.